I Gemmill1,2, K Young3. 1. NACI Influenza Working Group Chair, Kingston, ON. 2. Kingston, Frontenac and Lennox & Addington Public Health, Kingston, ON. 3. Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada, Ottawa, ON.
Abstract
BACKGROUND: Subunit and split virus inactivated influenza vaccines (IIV) are two commonly used types of seasonal influenza vaccines in Canada. The comparative effectiveness of these two formulations is particularly relevant for older adults, as older adults have reduced influenza vaccine effectiveness and experience more severe influenza than younger adults. OBJECTIVE: To compare the vaccine effectiveness and immunogenicity of unadjuvanted, standard-dose subunit IIVs versus unadjuvanted, standard-dose split virus IIVs in adults 65 years of age and older. METHODS: An a priori written protocol based on rapid review methods was developed that included studies published in 2007 or later in the EMBASE, MEDLINE and ClinicalTrials.gov databases with terms used in the objective. Due to the small number of records returned, hand searches of reference lists were completed, the publication date limit was removed, three additional databases (the Cochrane Central Register of Controlled Trials, Scopus and Web of Science) were searched, and studies including adults 60 years of age and older were included. Data from included studies were extracted into evidence tables and quality assessments were completed. The results were synthesized narratively. RESULTS: Eight eligible studies were identified. In the three studies that assessed vaccine effectiveness of subunit and split virus IIVs, there were no statistically significant differences in vaccine effectiveness in adults 65 years of age and older against laboratory-confirmed infection with any influenza virus strain, or against laboratory-confirmed infection with influenza A(H1N1), A(H3N2) or B virus, specifically. In the five studies that assessed immunogenicity, the findings were not consistent and the overall quality of immunogenicity evidence was weak. CONCLUSION: The National Advisory Committee on Immunization (NACI) concludes that there is insufficient evidence to determine significant differences in the vaccine effectiveness or immunogenicity of unadjuvanted, standard-dose subunit and split virus IIVs in adults 65 years of age and older (Grade I evidence).
BACKGROUND: Subunit and split virus inactivated influenza vaccines (IIV) are two commonly used types of seasonal influenza vaccines in Canada. The comparative effectiveness of these two formulations is particularly relevant for older adults, as older adults have reduced influenza vaccine effectiveness and experience more severe influenza than younger adults. OBJECTIVE: To compare the vaccine effectiveness and immunogenicity of unadjuvanted, standard-dose subunit IIVs versus unadjuvanted, standard-dose split virus IIVs in adults 65 years of age and older. METHODS: An a priori written protocol based on rapid review methods was developed that included studies published in 2007 or later in the EMBASE, MEDLINE and ClinicalTrials.gov databases with terms used in the objective. Due to the small number of records returned, hand searches of reference lists were completed, the publication date limit was removed, three additional databases (the Cochrane Central Register of Controlled Trials, Scopus and Web of Science) were searched, and studies including adults 60 years of age and older were included. Data from included studies were extracted into evidence tables and quality assessments were completed. The results were synthesized narratively. RESULTS: Eight eligible studies were identified. In the three studies that assessed vaccine effectiveness of subunit and split virus IIVs, there were no statistically significant differences in vaccine effectiveness in adults 65 years of age and older against laboratory-confirmed infection with any influenza virus strain, or against laboratory-confirmed infection with influenza A(H1N1), A(H3N2) or B virus, specifically. In the five studies that assessed immunogenicity, the findings were not consistent and the overall quality of immunogenicity evidence was weak. CONCLUSION: The National Advisory Committee on Immunization (NACI) concludes that there is insufficient evidence to determine significant differences in the vaccine effectiveness or immunogenicity of unadjuvanted, standard-dose subunit and split virus IIVs in adults 65 years of age and older (Grade I evidence).
Entities:
Keywords:
The National Advisory Committee on Immunization; influenza vaccine; split virus vaccine; subunit vaccine
Authors: Phil Edwards; Mike Clarke; Carolyn DiGuiseppi; Sarah Pratap; Ian Roberts; Reinhard Wentz Journal: Stat Med Date: 2002-06-15 Impact factor: 2.373
Authors: Danuta M Skowronski; Naveed Z Janjua; Gaston De Serres; Dale Purych; Vladimir Gilca; David W Scheifele; Marc Dionne; Suzana Sabaiduc; Jennifer L Gardy; Guiyun Li; Nathalie Bastien; Martin Petric; Guy Boivin; Yan Li Journal: J Infect Dis Date: 2012-08-07 Impact factor: 5.226
Authors: Janet E McElhaney; Dongxu Xie; W David Hager; Mary Beth Barry; Yazhen Wang; Alison Kleppinger; Catherine Ewen; Kevin P Kane; R Chris Bleackley Journal: J Immunol Date: 2006-05-15 Impact factor: 5.422
Authors: Giuseppe Del Giudice; Anne Katrin Hilbert; Roberto Bugarini; Ada Minutello; Olga Popova; Daniela Toneatto; Ines Schoendorf; Astrid Borkowski; Rino Rappuoli; Audino Podda Journal: Vaccine Date: 2006-01-19 Impact factor: 3.641